Get the latest news, insights, and market updates on DXCM (DexCom, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
The 5 Most Interesting Analyst Questions From DexCom’s Q4 Earnings Call
DexCom’s fourth quarter results reflected ongoing momentum in both product innovation and international expansion. Management attributed the quarter’s performance to the broad rollout of the G7 15-day sensor system in the U.S., which generated positive initial feedback from both customers and physicians due to improved wear time and accuracy. Operational improvements in manufacturing and logistics, such as reestablishing more efficient ocean shipping routes and addressing prior sensor deployment Feb 19, 2026 - $DXCM
Medtronic Posts Better-Than-Expected Earnings. Here’s Why the Stock Is Falling.
Medical device maker Medtronic reported quarterly earnings and net sales that topped consensus views. Medtronic on Tuesday posted fiscal third-quarter adjusted earnings of $1.36 a share, narrowly beating analysts’ forecasts of $1.34. Medtronic’s profit declined from the same period last year on a non-adjusted basis, slipping to $1.14 billion from $1.29 billion. Feb 17, 2026 - $DXCM
DexCom Inc. (DXCM) Reports Strong Performance While Maintaining Forward Outlook
DexCom Inc. (NASDAQ:DXCM) is one of the best medical technology stocks to invest in. On February 12, DexCom Inc. (NASDAQ:DXCM) shared its Q4 2025 earnings and reported $1.26 billion in quarterly revenue. This was well ahead of the $1.25 billion that Wall Street expected, and a 13% year over year growth. According to management, this […] Feb 15, 2026 - $DXCM
Why Is DexCom (DXCM) Stock Rocketing Higher Today
Shares of medical device company DexCom (NASDAQ:DXCM) jumped 7.3% in the morning session after it reported better-than-expected fourth-quarter 2025 financial results, beating analyst estimates for both revenue and earnings. Feb 13, 2026 - $DXCM
DXCM Q4 Deep Dive: New Product Launches and International Strategy Drive Outlook
Medical device company DexCom (NASDAQ:DXCM) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s revenue to be around $5.21 billion, close to analysts’ estimates. Its non-GAAP profit of $0.68 per share was 4.5% above analysts’ consensus estimates. Feb 13, 2026 - $DXCM
DexCom Expands G7 And Stelo To Deepen CGM Ecosystem Engagement
DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of its G7 15-day continuous glucose monitoring system, extending sensor wear time for users. The company is preparing a nationwide release of AI-enabled upgrades to its Stelo platform, aimed at providing deeper nutritional insights and personalized metabolic health guidance. These product moves expand DexCom's presence in diabetes and metabolic health management and introduce new data driven tools for everyday decision making. DexCom... Feb 13, 2026 - $DXCM
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple